Skip to main content
. 2017 Jun 9;76(7):1253–1262. doi: 10.1136/annrheumdis-2016-210457

Figure 1.

Figure 1

IRs for (A) SIE, (B) HZ (non-serious and serious) and (C) OI (excluding tuberculosis) over time for all tofacitinib doses. HZ, herpes zoster; IR, incidence rate; OI, opportunistic infection; SIE, serious infection event.